<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Intra-arterial (IA) thrombolytic intervention for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> has been challenged due to the risk of <z:mp ids='MP_0001914'>bleeding</z:mp> during the endovascular treatment of ruptured <z:hpo ids='HP_0002617'>aneurysms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We present the results of IA <z:chebi fb="0" ids="9605">tirofiban</z:chebi> infusion for thromboembolic complications during coil embolization in patients with ruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0001907'>Thromboembolic events</z:hpo> requiring thrombolytic intervention occurred in 39 (10.5%) cases during coil embolization of 372 consecutive ruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Maximal <z:hpo ids='HP_0002617'>aneurysm</z:hpo> diameters of 39 patients (mean age, 54.7 ± 13.2 years; 23 female, 16 male) ranged from 2.1 to 13.1mm (mean, 6.6 ± 3.0mm) </plain></SENT>
<SENT sid="4" pm="."><plain>The anterior communicating artery was the most common site (n=13), followed by the middle cerebral artery (n=9) and the posterior communicating artery (n=7) </plain></SENT>
<SENT sid="5" pm="."><plain>In this series, we used intracranial stents in 10 patients during the procedure </plain></SENT>
<SENT sid="6" pm="."><plain>Superselective IA <z:chebi fb="0" ids="9605">tirofiban</z:chebi> infusion through a microcatheter was performed to resolve <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and emboli </plain></SENT>
<SENT sid="7" pm="."><plain>We assessed the efficacy and safety of IA <z:chebi fb="0" ids="9605">tirofiban</z:chebi> infusion in patients with ruptured <z:hpo ids='HP_0002617'>aneurysms</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Intraarterially administered <z:chebi fb="0" ids="9605">tirofiban</z:chebi> doses ranged from 0.25 to 1.25mg (mean, 0.71 ± 0.26 mg) </plain></SENT>
<SENT sid="9" pm="."><plain>Effective thrombolysis or recanalization was achieved in 34 patients (87.2%), and three patients (7.7%) suffered distal migration of clots with partial recanalization </plain></SENT>
<SENT sid="10" pm="."><plain>The rest (5.1%) had no recanalization </plain></SENT>
<SENT sid="11" pm="."><plain>Nonconsequent <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> occurred in two patients (5.1%) after the procedure </plain></SENT>
<SENT sid="12" pm="."><plain>Thromboemboli-related <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> developed in eight patients, and only two patients remained infarction related disabilities </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: IA <z:chebi fb="0" ids="9605">tirofiban</z:chebi> infusion seems to be efficacious and safe for thrombolysis during coil embolization in patients with ruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> </plain></SENT>
</text></document>